<DOC>
	<DOCNO>NCT02475681</DOCNO>
	<brief_summary>This study evaluate efficacy obinutuzumab combination chlorambucil compare acalabrutinib combination obinutuzumab ( Arm B ) treatment previously untreated chronic lymphocytic leukemia ( CLL ) .</brief_summary>
	<brief_title>Elevate CLL TN : Study Obinutuzumab + Chlorambucil , Acalabrutinib ( ACP-196 ) + Obinutuzumab , Acalabrutinib Subjects With Previously Untreated CLL</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<mesh_term>Chlorambucil</mesh_term>
	<criteria>Men woman : ≥ 65 year age OR &gt; 18 &lt; 65 year age , provide meet least one follow criterion : 1 . Creatinine clearance 30 69 mL/min . 2 . A score high 6 Cumulative Illness Rating ScaleGeriatric . ECOG performance status 0 , 1 , 2 . Diagnosis CD20+ CLL . Active disease meeting ≥ 1 follow IWCLL 2008 criterion require treatment . Meet follow laboratory parameter : 1 . ANC ≥ 750 cells/μL , ≥ 500 cells/μL subject document bone marrow involvement , independent growth factor support 7 day assessment . 2 . Platelet count ≥ 50,000 cells/μL , ≥ 30,000 cells/μL subject document bone marrow involvement , without transfusion support 7 day assessment . Subjects transfusiondependent thrombocytopenia exclude . 3 . Serum AST ALT/SGPT ≤ 3.0 x ULN . 4 . Total bilirubin ≤ 1.5 x ULN . 5 . Estimated creatinine clearance ≥ 30 mL/min . Any prior systemic treatment CLL . Known CNS lymphoma leukemia . Known prolymphocytic leukemia history , currently suspect , Richter 's syndrome . Uncontrolled autoimmune hemolytic anemia idiopathic thrombocytopenia purpura . Major surgery within 4 week first dose study drug . Prior malignancy , except adequately treat lentigo maligna melanoma , nonmelanomatous skin cancer , situ cervical carcinoma , malignancy treat evidence active disease &gt; 3 year Screening low risk recurrence . Significant cardiovascular disease within 6 month screen . Known history infection HIV . History stroke intracranial hemorrhage within 6 month randomization . Known history bleed diathesis . Requires receive anticoagulation warfarin equivalent vitamin K antagonists within 7 day first dose study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>